<unk>  is an cytoprotective agent that is FDA approved for the treatment of reducing the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer and also to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.   Common adverse reactions include hypotension, nausea and/or vomiting, flushing/feeling of warmth, chills/feeling of coldness, malaise, fever, rash, dizziness, somnolence, hiccups, sneezing, and decrease in serum calcium concentrations.
Amifostine
ThioTEPA
Abciximab
Levoleucovorin
Picloxydine
Leucovorin 
Trilostane
Iofendylate